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Sequencing tests assaying panels of genes or whole exomes are widely available for cancer risk evaluation. However, methods for clas-
sification of variants resulting from this testing are not well studied. We evaluated the ability of a variant-classification methodology
based on American College of Medical Genetics and Genomics (ACMG) guidelines to define the rate of mutations and variants of un-
certain significance (VUS) in 180 medically relevant genes, including all ACMG-designated reportable cancer and non-cancer-associated
genes, in individuals who met guidelines for hereditary cancer risk evaluation. We performed whole-exome sequencing in 404 individ-
uals in 253 families and classified 1,640 variants. Potentially clinically actionable (likely pathogenic [LP] or pathogenic [P]) versus non-
actionable (VUS, likely benign, or benign) calls were 95% concordant with locus-specific databases and Clinvar. LP or P mutations were
identified in 12 of 25 breast cancer susceptibility genes in 26 families without identified BRCA1/2 mutations (11%). Evaluation of 84
additional genes associated with autosomal-dominant cancer susceptibility identified LP or P mutations in only two additional families
(0.8%). However, individuals from 10 of 253 families (3.9%) had incidental LP or Pmutations in 32 non-cancer-associated genes, and 9%
of individuals were monoallelic carriers of a rare LP or P mutation in 39 genes associated with autosomal-recessive cancer susceptibility.
Furthermore, 95% of individuals had at least one VUS. In summary, these data support the clinical utility of ACMG variant-classification
guidelines. Additionally, evaluation of extended panels of cancer-associated genes in breast/ovarian cancer families leads to only an in-
cremental clinical benefit but substantially increases the complexity of the results.Introduction
Approximately 10%–20% of breast and ovarian cancer
cases are associated with an inherited genetic predisposi-
tion.1 The identification of the breast cancer susceptibility
genes BRCA1(MIM: 113705) and BRCA2 (MIM: 600185)
has demonstrated the powerful impact that knowledge of
an underlying inherited susceptibility to cancer can have
on an individual’s clinical care.2 A number of potential
breast-cancer-susceptibility (MIM:114480) genes and al-
leles have been identified3 by large-scale genome-wide as-
sociation studies4 and by approaches based on massively
parallel sequencing5–11. As massively parallel sequencing
declines in cost, application of multigene panels in clinical
practice is becoming commonplace in genetic cancer risk
assessment.12
A number of studies using multigene panels to evaluate
breast or ovarian cancer risk have definedmutation rates in
well-established genes;13–18 however, hereditary cancer1Department of Medicine, Division of Hematology-Oncology, Perelman Scho
USA; 2Department of Health Sciences Research, Mayo Clinic, Rochester, MN 5
Clinical Genetics Service, Memorial Sloan-Kettering Cancer Center, New York
Columbia, Vancouver, BC V6T 1Z4, Canada; 5Department of Medical Oncolo
USA; 6Department of Population Sciences, Beckman Research Institute, City of
lational Medicine and Genetics, Perelman School of Medicine at the University
Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA; 9Abramson
vania, Philadelphia, PA 19104; 10Weill Cornell Medical College, New York, NY
stitutes of Health, Bethesda, MD 20892, USA




2016 by The American Society of Human Genetics. All rights reserved.panels with up to 110 genes are clinically available. Genes
selected for many clinical panels have varying levels of
evidentiary support for their role in inherited cancer
susceptibility; such genes range from those in whichmuta-
tions are associated with well-defined risks of specific can-
cers tomore recently defined susceptibility genes for which
the cancer risks remain ill defined. Although the National
Cancer Care Network (NCCN) has expanded discussion of
the issues with multigene panel testing in their recent
guidelines on hereditary breast and ovarian cancer,1
many questions remain. For example, the expected fre-
quencies of mutations and variants of uncertain signifi-
cance (VUS) in many of the genes with a postulated but
unproven association with breast and/or ovarian cancer
are not well defined.
Recently, large multigene ‘‘medical exome’’ panels and
whole-exome sequencing also have been suggested as a
diagnostic approach for cancer risk assessment.19,20 Thus,
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in disease-related genes not associated with the phenotype
driving genetic testing might be identified. Incidental, also
referred to as secondary, findings that are suggested by the
American College of Medical Genetics and Genomics
(ACMG) to be clinically returned21 might complicate the
use of large-panel or exome-genetic-testing approaches
because the rate of incidental findings in individuals pre-
senting for evaluation of cancer susceptibility is un-
known22,23.
An additional overarching issue in the use of multigene-
panel or exome-sequencing-based approaches for cancer
risk evaluation is that variant classification differs between
clinical laboratories, and this difference often leads to
inconsistent classification of individual variants. Thus, a
standardized framework for the evaluation of the clinical
significance of variants is needed,12 and the ACMG
recently published guidelines for variant classification.24
However, practical methodologies for variant classification
based on these guidelines have not been studied in a
cohort of individuals undergoing sequencing for inherited
cancer risk.
We performed whole-exome sequencing of 404 individ-
uals representing 253 families that were at high risk for
breast and/or ovarian cancer and met established guide-
lines for cancer risk evaluation, and we systematically
applied an ACMG-guideline-based methodology of variant
classification in a research setting to classify 1,640 variants
in 180 medically relevant genes, including all genes for
which incidental findings are deemed reportable by
ACMG. We report the rate of concordance of variant clas-
sification by this methodology with calls in well-curated,
locus-specific databases, Clinvar and the Human Gene
Mutation Database (HGMD). In addition, we report the
rates of pathogenic or likely pathogenic (LP/P) variants,
benign or likely benign (B/LB) variants, and variants of un-
certain significance (VUS) in these 180 genes in families
affected by breast or ovarian cancer. We provide evidence
that increasing the number of evaluated genes in individ-
uals undergoing evaluation for breast or ovarian cancer
risk does not increase the rate of molecular diagnosis but
is coupled with a substantial burden of incidental and un-
certain results.Subjects and Methods
Sample Acquisition
The study population was ascertained from academic and commu-
nity hospital sites affiliated with the Penn Cancer Network, the
Mayo Clinic, Memorial Sloan Kettering Cancer Center, and the
City of Hope Clinical Cancer Genomics Community Research
Network. Acquisition of the human samples was approved by
the institutional review boards of the corresponding institutions,
and informed consent was obtained from each participant for
use of their samples in genetic studies. Individuals who were
eligible for the study had to (1) be affected with breast or ovarian
cancer and belong to a family with greater than or equal to three
first- to third-degree relatives who had breast or ovarian cancer802 The American Journal of Human Genetics 98, 801–817, May 5, 2and were under age 60 (familial breast cancer, FBC); (2) have a
diagnosis of primary breast and primary ovarian cancer (BrOv);
or (3) have a diagnosis of early-onset breast cancer (age < 45,
EOBC). In families with multiple affected family members, one
or more (if available, Table 1) individuals with the youngest ages
of cancer diagnoses were chosen for sequencing. In certain cases,
family members were also chosen for sequencing if they were obli-
gate carriers or had a non-breast or non-ovarian malignancy (four
obligate carriers, two cases of uveal melanoma, one case with kid-
ney adenocarcinoma) and were valuable in segregation analysis.
Whole-Exome Sequencing and Initial Bioinformatic
Analysis
Exome capture and enrichment were performed with the
SureSelect liquid-based hybrid capture system from Agilent Tech-
nologies. Paired-end sequencing was performed on an Illumina
Hi-Seq 2000 or 2500 (2 3 100 bp). Paired-end reads in the form
of FASTQ files were aligned to the GRCh37 version of the human
genome with BWA or Novalign to generate BAM files. Variant call-
ing was performed with the Picard/GATK pipeline. The infor-
matics approaches to harmonizing the data from different centers
were performed as previously described.25 The BioR toolkit26 and
ANNOVAR27 were used for annotating variants with CAVA variant
nomenclature,28 known pathogenicity information from the Hu-
man Gene Mutation Database (HGMD)29 and Clinvar,30 and
missense predictions from dbNSFP.31 Alternative alleles with less
than five reads and/or a frequency less than 20% were excluded.
Variants were also excluded from analysis if they had >5% allele
frequency in the study cohort and if they either were absent in
EVS6500 and 1000 Genomes or had greater than 20-fold higher
frequency than in EVS6500 and 1000 Genomes. All variants pass-
ing the sequencing quality-control filters, regardless of database
population frequency, underwent classification.
Gene Selection for Analysis
Medically relevant genes were defined as known inherited cancer
susceptibility genes and all genes related to non-cancer disease risk
that were included in the ACMG suggested list of reportable inci-
dental findings21 (Table S1). The cancer susceptibility genes (148
genes) included all genes reported in Rahman32 and/or in the can-
cer susceptibility gene list of the Institute for Cancer Research (135
genes) and any additional genes found on commercially available
cancer risk evaluation panels12 (13 additional genes). All 66 genes
reported to be associated with adult inherited solid-tumor cancer
syndromes by the Cancer Gene Census are included in this list.
Overview of Variant Classification
A systematic methodology based on the variant-classification
guidelines of the ACMG24 was developed (Figure S1 and Table
S2). The guidelines list 27 variant attributes for determination of
pathogenicity or benign impact of a variant: very strong evidence
of pathogenicity (PVS1), strong evidence of pathogenicity (PS1–
PS4), moderate evidence of pathogenicity (PM1–PM6), supporting
evidence of pathogenicity (PP1–PP5), stand-alone evidence of
benign impact (BA1), strong evidence of benign impact (BS1–
BS4), and supporting evidence of benign impact (BP1–BP6). The
criteria for each attribute, method of determination for each crite-
rion, and rule used to combine data, if needed, for calling each
variant attribute in the present sequencing project are described
below and listed in Table S2 and Figure S1. The ACMG guidelines
combine these variant attributes via another set of scoring rules016
into a variant call, namely P, LP, LB, and B; all possible combina-
tions are listed in Table S3, whichwas used for generating raw calls.
No adjustment of criteria weighting was performed for this anal-
ysis. All raw calls then underwent a manual dual-person review
process (KNM, TPS) for consideration of changes to create final
calls. Adjustments, or ‘‘manual overrides,’’ were based on interpre-
tation of the variant in the context of the individual phenotype
and disease spectrum associated with the gene and in the context
of in-depth reviews of the literature and locus-specific databases.
Criteria for a detailed override evaluation were (1) raw calls discor-
dant with LSDBs or Clinvar; (2) all variants with LP or P raw calls;
and (3) all truncating variants. The study team needed to agree on
all calls. The raw data for the variants are shown in Table S4, and
the variant analysis is shown in Table S5.
Determination of PM2, BA1, BS1, and BS2
Variants were bioinformatically annotated with population allele
frequency from EVS6500 and 1000 Genomes and with sample-
set allele frequency. For all genes associated with autosomal-domi-
nant (AD) cancer susceptibility, variants found at greater than 5%
population allele frequency were coded 1 for BA1, and all variants
found at 0.5%–5% population allele frequency were coded 1 for
BS1. All variants that occurred in genes associated with AD cancer
susceptibility and that were found at greater than 5% frequency in
the sample set, regardless of population allele frequency, were
coded 1 for BS2. For all genes associated with autosomal-recessive
(AR) cancer susceptibility, heterozygous carrier frequencies and
disease prevalences were obtained from GeneReviews (Table S1).
Because individual mutant carrier frequencies in HFE (MIM:
613609) and SERPINA1 (MIM: 107400) exceed 1%, cutoffs were
adjusted to a population frequency of 25% for BA1, a population
frequency of 10% for BS1, and a dataset frequency of 25% for
BS2. All variants absent in both EVS6500 and 1000 Genomes
were coded as 1 for PM2.
Determination of PP5 and BP6
Variants were annotated with classifications from the publicly
available database Clinvar.30 Variants were coded as 1 for PP5 if
(1) they had non-conflicting LP or P calls; (2) they were submitted
by commercial laboratories; and (3) supporting data were not
included for independent evaluation. Variants were coded as 1
for BP6 if (1) they had non-conflicting likely benign or benign
calls; (2) they were submitted by commercial laboratories; and
(3) supporting data were not included for independent evaluation.
Variants were coded as 0 for both PP5 and BP6 if (1) they had un-
certain calls, (2) they had conflicting calls; (3) calls submitted by
commercial laboratories or expert consensus and supporting
data were included and therefore could be independently evalu-
ated; or (4) they had OMIM calls. If the variant was not found in
Clinvar, an ‘‘nd’’ designation was given.
Determination of PVS1; PP2 and BP1; PM3 and BP2;
and PP4
The following ‘‘gene level’’ characteristics needed to be deter-
mined for the analyzed genes in order for the ACMG guidelines
for variant classification to be applied: (1) mechanism of mutation
leading to disease, i.e., loss of function (LOF) or gain of function
(for PVS1) and whether missense mutations are typically patho-
genic in the gene (for PP2 and BP1); (2) mode of inheritance,
i.e., autosomal dominant, autosomal recessive, semi-dominant,
X-linked recessive (for PM3 and BP2); and (3) whether single mu-The Amtations in the gene lead to the studied phenotype, namely breast
cancer susceptibility. These determinations are reported in Table
S1. Each was determined by review of the literature and OMIM.
All variants for genes for which LOF is not a mechanism of disease
were coded as 0 for PVS1. For genes in which LOF is a mechanism
of disease, PVS1 was coded as 1 for all nonsense and frameshift
mutations not in the last exon of the gene and for all splicing
mutations at the 2, 1, þ1, and þ2 sites; all other variants
were coded as 0 for PVS1. For determination of whether missense
mutations are typically pathogenic in a gene, all variants of the
evaluated genes were downloaded from Clinvar, and ‘‘pathogenic
mutations’’ were defined as those that fit the following three
criteria: (1) germline origin; (2) review status classified by multiple
submitters, reviewed by an expert panel, or classified by a single
submitter when the submitter was a CLIA-approved laboratory
or OMIM; and (3) clinical significance classified without conflict
as P or LP (Table S6). The number of missense and truncating
mutations were tallied, and missense mutations were considered
typically pathogenic for a gene if >50% of the mutations were
missense and >10 variants were available for evaluation of the
claim (Table S1) or if the mechanism of mutation for the gene
was gain of function. All missense variants for genes where
missense mutations are not typically considered pathogenic
were coded as 1 for BP1 and 0 for PP2; all missense variants for
genes where missense mutations are typically considered patho-
genic were coded as 0 for BP1 and as 1 for PP2. If not enough
variants were present in Clinvar for this analysis, genes were coded
as 0 for both BP1 and PP2. Finally, because breast cancer suscepti-
bility is not a disease with a single etiology, all variants were coded
as 0 for PP4 (Table S1).Determination of PM1
The coordinates of Pfam domains in the analyzed genes were
downloaded from UCSC genome browser table function. Domain
coordinates were then validated with Uniprot. Only domains with
documented evidence of being in critical hotspot regions or well-
characterized functional domains as documented in the Atlas of
Genetics and Cytogenetics in Oncology and Haematology
or NCBI GeneReviews were counted for PM1 designation
(Table S1). Variants at hotspots or in critical and well-established
functional domains were coded as 1 for PM1; all other variants
were coded as 0.Determination of PP1 and BS4 and of BP5
If other variants in cancer susceptibility genes were found in an in-
dividual with an LP or P mutation in a high-risk breast cancer sus-
ceptibility gene, specifically BRCA1 or BRCA2, CDH1 (MIM:
192090), PALB2 (MIM: 610355), PTEN (MIM: 601728), STK11
(MIM: 602216), or TP53 (MIM: 191170), they were coded as 1
for BP5. A subset of variants came from families with between
two and seven affected individuals sequenced. For all cancer sus-
ceptibility genes, if the variant was found in all affected members
of a family, it was coded as 1 for PP1 and as 0 for BS4. If the variant
was not found in any affected members of a family, it was coded as
0 for PP1 and as 1 for BS4. Variants identified in singleton samples
were coded as 0 for both PP1 and BS4. This designation was not
used for non-cancer-associated genes.Determination of PP3 and BP4
Non-synonomous variants (n ¼ 1554) were annotated with calls
from 13 in silico callers with the BioR toolkit26 as above; fourerican Journal of Human Genetics 98, 801–817, May 5, 2016 803
(CAROL, Condel, RadialSVM, and CADD) were callers that
incorporate other callers or ‘‘multiple callers’’ and nine (LRT,
MutationAssessor, MutationTaster, Polyphen2, HDIV, SIFT,
FATHMM, PhyloP, GERPþþ, and SiPhy) were ‘‘standalone callers.’’
Deleterious or benign predictions or recommended cutoffs were
included for CAROL, Condel, Radial SVM, LRT, MutationAssesor,
MutationTaster, PolyPhen2 HDIV, SIFT, FATHMM, and PhyloP.
The number of variants with no call and the proportion of
missense calls that were called benign versus deleterious are
shown in Table S7. On average, 61% of calls were benign, and
39% of calls were deleterious for callers with provided cutoffs.
Because no predictions or cutoffs were included for CADD,
GERPþþ, or SiPhy, a deleterious cutoff was empirically derived
by determination of the value that cause 75% of calls to be benign
and 25% of calls to be deleterious. Two methodologies, a ‘‘uni-
form’’ model and a ‘‘majority rules’’ model, were then tested for
use of the in silico data to determine PP3 and BP4 attribute calls.
The uniform model was used in the final variant classifications.
In the uniform model, variants were coded as 1 for BP4 and as 0
for PP3 if all callers uniformly had a benign call, were coded as 0
for BP4 and as 1 for PP3 if all callers uniformly had a deleterious
call, and were coded as 0 for both BP4 and PP3 if callers were
inconsistent. In the majority-rules model, the percentage of dele-
terious calls from the multiple caller tools and standalone caller
tools were determined. Variants were coded as 1 for PP3 and as
0 for BP4 if more than 50% of multiple and standalone caller tools
had deleterious calls, coded as 1 for BP4 and as 0 for PP3 if fewer
than 50% did, and coded as 0 for both PP3 and BP4 if the multiple
and standalone percentages were inconsistent.Determination of PM4 and BP3
For all variants classified as in-frame deletions or insertions, the
position of the variant was queried in the UCSC genome browser
via the ‘‘RepeatMasker’’ for all repeat types. Variants found in a
repetitive region were coded as 1 for BP3 and as 0 for PM4; variants
not found in a repetitive region were coded as 0 for BP3 and as 1
for PM4.Determination of PS1 and PM5
HGMD and Clinvar were used for manual identification of vari-
ants found at a cDNA position where an alternative codon change
was known to lead to the same pathogenic amino acid change
(PS1). The databases were also used for manual identification of
whether a variant was found at a protein position where an alter-
native codon change leads to a different pathogenic amino acid
change (PM5). If the variant was not found in either database,
an ‘‘nd’’ designation was given; if it was found and PS1 or PM5
was true, the variant was queried in Clinvar and Pubmed so that
the pathogenicity call could be independently evaluated before
assignment of code 1 for either variable.Determination of PS3 and BS3; PS4; PM6; and PS2
For determination of PS3 and BS3, variants that were identified in
the HGMD Professional version and that had references listed as
‘‘primary literature’’ and ‘‘functional characterization’’ or that
were identified in Clinvar and had Pubmed references listed under
‘‘Supporting Observations’’ were evaluated for whether they re-
ported the variant’s effect on protein function. Primary literature
was queried so that additional references could be identified.
The literature was then reviewed, and if a benign effect was re-
ported the variant was coded as 1 for BS3 and as 0 for PS3. If a804 The American Journal of Human Genetics 98, 801–817, May 5, 2variant was reported to cause a deleterious effect in a functional
assay, the variant was coded as 0 for BS3 and as 1 for PS3. Variants
that showed intermediate effects in functional assays or inconsis-
tent data in different publications were coded as 0 for both BS3
and PS3. References for functional assays were found and used
for classification in 12% of variants (Table S8). All variants that
were identified in the HGMD Professional version or Clinvar and
that had references describing case control studies were evaluated
for the determination of an odds ratio of disease; primary literature
was queried so that additional references could be identified. Var-
iants evaluated in a case control study of more than 1,000 cases
and 1,000 controls and showing an odds ratio greater than 2 for
cancer risk were coded as 1 for PS4; otherwise, they were coded
as 0; if no such study existed, an ‘‘nd’’ designation was given. No
variants were considered or known to be de novo in this study
(PM6 and PS2).
Validation of the Variant Classification Methodology
for Variant Calling
The variant calls for genes for which a ‘‘well-curated’’ locus-specific
database (LSDB) exist (URLs are listed in Table S1 and Web Re-
sources) were compared to both the raw and final calls as gener-
ated by the methodology in this paper. A ‘‘well-curated’’ LSDB
was defined in this study as one in which variants were classified
into a five-class variant-classification system or provided prior
probability of pathogenicity scores. Genes that were associated
with AD cancer susceptibility and that had well-curated LSDBs
were AIP (MIM: 605555), APC (MIM: 611731), BRCA1, BRCA2,
GJB2 (MIM: 121011), mismatch repair cancer syndrome genes
(MLH1 [MIM: 120436], MSH2 [MIM: 609309], MSH6 [MIM:
600678], and PMS2 [MIM: 600259]), RET (MIM: 164761), TERT
(MIM: 187270), TSC1 (MIM: 605284),and TSC2 (MIM: 191092).
Genes that were associated with AR cancer susceptibility and
had well-curated LSDBs were COL7A1 (MIM: 120120), FAH
(MIM: 613871), GBA (MIM: 606463), HFE, MUTYH (MIM:
604933), SBDS (MIM: 607444), SERPINA1,and WRN (MIM:
604611). The non-cancer-associated genes that had well-curated
LSDBs were DSC2 (MIM: 125645), DSG2 (MIM: 125671), DSP
(MIM: 125647), KCNQ1 (MIM: 607542), PKP2 (MIM :602861),
RYR1 (MIM: 180901), and TMEM43 (MIM: 612048).
Statistical Analyses
Means of continuous variables were compared via a two-tailed Stu-
dent’s t test. Outliers were excluded on the basis of Grubb’s test
(extreme Studentized deviate test). Rates in different groups were
compared with a Fisher’s exact test of significance.Results
404 individuals from 253 families at high risk for breast
and/or ovarian cancer (Table 1) underwent whole-exome
sequencing (WES). Overall, 1,640 unique non-silent
exonic germline variants (allelic fraction greater than
20%) were identified in 167 of the 180 genes. On average,
for genes with at least one variant identified, 105 11 non-
silent variants were found per gene (range 1–63 total vari-
ants identified per gene). No non-silent variants were
found in eight cancer-associated genes, namely AKT1
(MIM: 164730), CDC73 (MIM: 607393), CDK4 (MIM:
123829), HRAS (MIM: 190020), MAX (MIM: 154950),016
Table 1. Clinical Characteristics of the Population
Cohortsa
A B C D
Number of familiesb (total
n ¼ 253)
10 243 28 215
Number of individuals
(total n ¼ 404)
15 389 45 344
Number of families w/1
individual sequenced
6 137 17 120
Number of families w/2
individuals sequenced
3 75 6 69
Number families w/R 3
individuals sequenced
1 31 5 26
High-Risk Criteria (>1 family member if >1 Sequenced)
n Percent n Percent n Percent n Percent
Familial breast cancer 10 100 169 70 18 64 151 70
Breast and ovarian cancer 0 0 81 33 10 36 71 33
Early-onset breast cancer 7 70 128 53 15 54 113 53
Ovarian cancer without
breast cancer
0 0 9 4 0 0 9 4
Other member with
familial breast cancerc
1 10 7 3 0 0 7 3
Clinical or Family Historyd
n Percent n Percent n Percent n Percent
Average age of onset of
breast cancer (range)
43 (26–58) 48 (19–77) 48 (19–76) 48 (26–77)
Contralateral breast
cancer
2 20 40 16 6 21 34 16
Closest relative with
breast cancer is FDR
8 80 169 70 16 57 153 71
Closest relative with
breast cancer is SDR
2 20 39 16 7 25 32 15
Closest relative with
breast cancer is TDR
0 0 16 7 0 0 16 7
No family history of
breast cancer
0 0 19 8 5 18 14 7
Ovarian cancer in
FDR–TDR
6 60 48 20 3 11 45 21
Prostate cancer in
FDR–TDR
2 20 71 30 8 29 63 29
Pancreatic cancer in
FDR–TDR
2 20 28 12 6 21 22 10
LFS cancere in FDR–TDR 3 30 67 28 12 43 55 26
Lynch cancerf in
FDR–TDR
6 60 115 47 17 61 98 46
aCohort A: individuals with identified BRCA1/2mutations. Cohort B: entire cohort of individuals without identified BRCA1/2mutations. Cohort C: subset of cohort
B with identified LP or P mutations in cancer susceptibility genes. Cohort D: subset of cohort B without identified LP or P mutations in cancer susceptibility genes.
bSome families were represented by more than one sequenced individual.
cMembers of a family at high risk for familial breast cancer who were either obligate carriers or affected with a non-breast, non-ovarian malignancy.
dReference is proband. Abbreviations are as follows: FDR, first-degree relative; SDR, second-degree relative; and TDR, third-degree relative.
eLFS (Li Fraumeni Syndrome) cancer is defined as sarcoma, leukemia, brain cancer, and adrenocortical carcinoma.
fLynch cancer is defined as colon, uterine, renal, stomach, hepatobiliary, small bowel, and sebaceous neoplasm.
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Table 2. Manual Overrides in Variant Classification
Override Change Number of Calls
Percent of Overrides
(Percent of All Calls) Override Reasons
Downgrade, VUS > LB 88 48% (0.5%) In silico analysis (62), frequency in dataset (22), variant
specific (4)a
Upgrade, B > VUS 58 32% (0.4%) Absent in EVS (51), nonfunctional in assays (7)
Upgrade, VUS > LP 33 18% (0.2%) Truncating mutations (27), known hearing-loss mutations
in GJB2 (4), segregation in 3/3 affected family members with
in silico, population and dataset frequency data (2)
Upgrade, B > P, VUS > P 2 1.1% (< 0.1%) Frequent HFE mutations
Downgrade, LP > VUS 1 0.5% (< 0.1%) Variant in oncogene and predicted LP but not in COSMIC or
TCGA, no functional data to support
aRET c.2372A>T (p.Tyr791Phe) is a known benign variant; SMARCB1 c.1A>G (p.Met1?) has three immediately distal ATGs; and DSC2 c.2686_2687dupGA
(p.Ala897Lysfs*4) (NM_004949.4) and BRCA2 c.10095_10096insGAATTATATC (p.Ser3366Glufs*5) (NM_000059.3) are distal to the last known truncating
benign polymorphism in the corresponding gene.PPM1D (MIM: 605100), PRKAR1A (MIM: 188830), PTEN,
RMRP (MIM: 157660), and SDHAF2 (MIM: 613019). In
addition, no non-silent variants were found in four non-
cancer-associated genes, namely ACTA2 (MIM: 102620),
ACTC1 (MIM: 102540), TNNI3 (MIM: 191044), and
TPM1 (MIM: 191010). Coverage was examined for these
genes, and read depth was determined to be sufficient
(all genes had minimum read depths of 373). Individuals
had on average 97 5 12 nonsynonymous variants and
small insertion or deletion variants (indels) in the 180 eval-
uated genes (range: 23–128 variants per individual).
In order to evaluate the ACMG variant classification
guidelines24 in a research setting, we developed a compre-
hensive variant analysis methodology based on these
guidelines (Table S2, Figure S1). In brief, the presence of
27 attributes with varying levels of support for pathoge-
nicity or benign variation was determined for each variant,
leading to raw calls of benign (B), likely benign (LB),
variant of uncertain significance (VUS), likely pathogenic
(LP), or pathogenic (P) for each variant (Table S8). All
raw calls were then manually reviewed and adjusted to
final calls. Detailed analyses were performed for all variants
with an LP or P raw call, all truncating variants, and all var-
iants with discordant raw calls as compared to calls in
LSDBs and Clinvar (306 variants; 19%). The decision to
override the initial call was made for 182 calls (11% of
the total, 59% of those reviewed) (Table 2).
To apply the ACMG variant-classification guidelines, a
number of a priori decisions were required regarding how
the attributes would be determined (Figure S1). As one
example, two methods, based on a majority-rules or uni-
form model to convert data from 13 in silico callers into
a PP3 or BP4 (in silico data) attribute call (see Subjects
andMethods) were examined. The uniformmodel resulted
in inconsistent PP3 or BP4 attribute calls for 82% of vari-
ants, consistent benign in silico calls resulting in BP4 ¼ 1
for 17% of variants, and consistent deleterious in silico
calls resulting in PP3 ¼ 1 for 1% of variants (Figure S2A).
The majority-rules model resulted in inconsistent PP3 or
BP4 attribute calls in 8% of variants, consistent benign806 The American Journal of Human Genetics 98, 801–817, May 5, 2BP4 ¼ 1 for 72% of variants, and consistent deleterious
PP3 ¼ 1 for 20% of variants (Figure S2A). Despite this,
83% of final calls were no different when onemodel versus
the other was used (Figure S2B). Use of the majority-rules
model instead of the uniform model alleviated the need
for LB/B-to-VUS or LP/P-to-VUS override calls for 4% of
all nonsynonymous variants (Figures S2B and S2C).
Furthermore, use of the majority-rules model instead of
the uniform model decreased the VUS rate by resulting
in 197 LB or B calls and five LP or P calls that were a VUS
call with the uniform model (13% of all nonsynonymous
variants; Figure S2D). However, the five final-call VUSs
that called LP or P when the majority-rules model was
used instead of the uniformmodel did not have enough in-
formation to support an LP or P call on the basis of our
analysis (Figure S2E). The uniform model was therefore
used in the final variant-classification methodology as a
more conservative methodology, despite the resultant
higher VUS rate.
Figure 1A shows how our methodology classified vari-
ants listed as pathogenic in 28 well-curated locus-specific
databases (LSDBs) for which calls into a three- or five-class
system are utilized (see Table S1 and Web Resources for
LSDBs used). In order to evaluate the concordance of the
ACMG variant-classification-basedmethodology to LSDBs,
we analyzed 219 variants that were identified both in the
sequenced individuals and in LSDBs. Overall, 74% of raw
calls and 83% of final calls were absolutely concordant
(Figure 1B). Raw calls in genes associated with AD cancer
susceptibility had a higher rate of absolute concordance
than genes associated with AR cancer susceptibility (77%
versus 64%, p ¼ 0.04). However, no difference in absolute
concordance was seen for final calls (84% versus 77%, p ¼
NS), as expected given that LSDB data were considered in
the manual-override process. Because LB, B, and VUS calls
are not acted upon clinically, whereas LP or P mutations
could be considered in screening, treatment, and reproduc-
tive risk-reduction recommendations, we next compared
the rate of concordance on the basis of potential clinical
actionability. We found that 92% of raw calls and 95% of016
final calls were concordant with LSDB calls (Figure 1C),
and all 18 of the discordant raw calls were LSDB-called
P or LP variants classified as B, LB, or VUS by our method-
ology. Nine (50%) of these were discordant raw calls but
concordant final calls, including the known HFE and
SERPINA1 mutations and truncating variants in GJB2 and
MSH6 (associated with AD cancer susceptibility), WRN
(associated with AR cancer susceptibility), and the non-
cancer-associated gene PKP2. The nine final calls that
were discordant with LSDBs were missense variants in
AIP, GJB2, and RET (associated with AD cancer susceptibil-
ity); COL7A1 (associated with AR cancer susceptibility);
and the non-cancer-associated gene RYR1. In all cases the
literature was extensively reviewed, and there was not
enough support for an LP or P call or, in some cases,
enough support for a B or LB call, such as for a benign
RET variant.33,34 Raw calls in genes associated with AD
cancer susceptibility and non-cancer-associated genes
showed higher potential clinical actionability concor-
dance, 93% and 95%, respectively, than genes associated
with AR cancer susceptibility (77%, p ¼ 0.03, p ¼ 0.04),
although final calls showed similar potential actionability
concordances (96%, 96%, and 91%, respectively) with
LSDBs.
We then utilized our methodology based on ACMG
guidelines to classify the remaining 1,421 variants. Of
the 1,421 variants, 482 (34%) were found in Clinvar and
355 (25%) in HGMD (245 or 17% in both databases). Abso-
lute call concordances of raw calls and final calls compared
to Clinvar were 68% and 77%, respectively. Potential ac-
tionability concordances of raw calls and final calls
compared to Clinvar were 93% and 95%, respectively
(Figure S3). Absolute and potential actionability concor-
dance was 24% and 44% between raw calls and HGMD,
respectively, and 30% and 47% between final calls and
HGMD, respectively. Absolute and potential actionability
concordance were 33% and 49%, respectively, for compar-
isons of the same calls within Clinvar and HGMD
(Figure S3). Figure 1D shows the attribute distribution
and concordance with Clinvar and HGMD for the 46 LP
and P variants not found in LSDBs and identified in this
study. It is important to note that 25 of the 46 LP or P calls
(54%) were override calls from VUS (Table 2). These calls
included 11 variants in genes associated with AD
cancer susceptibility (ATM [MIM: 607585], BARD1
[MIM: 601593], CDKN2A [MIM: 600160], FANCM [MIM:
609644], MRE11A [MIM: 600814], PALB2, RAD50 [MIM:
604040], RAD51D [MIM: 602954]), eight variants in
genes associated with AR cancer susceptibility (ERCC2
[MIM: 126340], ERCC3 [MIM: 133510], FANCD2 [MIM:
613984], GBA, PRF1 [MIM: 170280], and WRN), and
six variants in non-cancer-associated genes (APOB [MIM:
107730], DSP, MYBPC3 [MIM: 600958], SCN5A [MIM:
600163], and SMAD3 [MIM: 603109]).
The distribution of B, LB, VUS, LP, and P variants accord-
ing to our methodology derived from ACMG guidelines
varied widely between the 180 assayed genes (Figure 2AThe Amand Figures S4 and S5). Thirty-five genes had at least one
LP or P final call; there was a large range in the number
of variants identified per gene, and the majority of genes
had only VUSs (Figures 2B–2E and Figures S4 and S5).
Well-defined breast cancer susceptibility genes had a
significantly lower average rate of VUS final calls (31%)
in comparison to other genes associated with AD cancer
susceptibility (54%, p ¼ 0.002), genes associated with AR
cancer susceptibility (58%, p ¼ 0.002), and non-cancer-
associated genes (71%, p ¼ 1.1 3 105) (Table 3). In order
to explore potential causes for this observation, we calcu-
lated the average number of attributes per classified variant
for each gene (Table S9). Attributes were only considered if
they required literature or database evaluation (namely
PS1, PS3 and BS3, PS4, PM1, PM5, PP2 and BP1, and PP5
and BP6), so that attributes available for all variants were
not included. On average, well-established breast cancer
susceptibility genes had 2.3 literature or database attributes
contributing to a variant call, whereas other genes associ-
ated with AD cancer susceptibility, genes associated with
AR cancer susceptibility, and non-cancer-associated genes
on average had significantly fewer attributes contributing
to variant calls (1.2, 0.8, and 1.6, respectively; p < 0.006
for all comparisons) (Table 3).
We next determined the distribution of LP and P muta-
tions classified by our ACMG-guidelines-based methodol-
ogy in known or proposed breast cancer susceptibility
genes in individuals without identified BRCA1/2 muta-
tions. As shown in Figure 3A, in these 389 individuals rep-
resenting 243 families, 2.5% were found to have LP or P
mutations in high-risk breast cancer susceptibility genes
TP53, CDH1, and PALB2, and 4.9% were found to have
such mutations in ATM and CHEK2. An additional 3.2%
of families had mutations in the remaining known or pro-
posed breast cancer susceptibility genes. Interestingly,
although LP and Pmutations in the high-risk breast cancer
susceptibility genes were found at similar rates across
subcategories of individuals, ATM and CHEK2 LP and P
mutations were significantly less frequent in the subset
of individuals with multiple primary breast or ovarian tu-
mors than in those with familial breast cancer or early-
onset breast cancer (p < 0.01), whereas mutations in the
rest of the genes associated with AD cancer susceptibility
were found significantly less frequently in those with
early-onset breast cancer (p < 0.02) (Figure 3B). The per-
sonal and family history of individuals with LP or P vari-
ants in known or proposed breast cancer susceptibility
genes is shown in Table S10. Overall, 11% of families had
LP or P mutations in known and/or proposed breast cancer
susceptibility genes, and 28% of families had at least one
family member with a VUS in one of these genes, leading
to a ratio of VUS to LP or P mutation identification rate
of 3:1 (Table 4).
Given that the genetic etiology associated with breast
cancer risk remained unexplained in 89% of the families
without identified BRCA1/2 mutations despite evaluation
of 25 known or proposed breast cancer susceptibilityerican Journal of Human Genetics 98, 801–817, May 5, 2016 807
Figure 1. Use of A Methodology Based on ACMG Variant-Classification Guidelines to Identify Variants in 180 Clinically Relevant
Genes in Individuals with Breast Cancer
(A) Heat map showing the individual attributes leading to the raw and final calls of well-curated locus-specific database (LSDB)-classified
pathogenic variants found by exome sequencing in individuals at high risk for breast and/or ovarian cancer. Genes are separated into
(legend continued on next page)
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genes, we assessed the possible impact of including addi-
tional genes associated with AD cancer susceptibility on
rates of mutation and VUS identification in this cohort.
The addition of 74 genes associated with AD cancer suscep-
tibility led to identification of LP or P mutations in an
additional 0.8% of families, leaving 89% of families with
no LP or P mutation in any gene known to be associated
with AD cancer susceptibility (Figure 3A and Table 4).
However, 77% of families had a VUS for one of these
genes, leading to a 95:1 ratio of VUS-positive to LP- or
P-positive families (Table 4). Of note, in addition to
these pathogenic mutations, five individuals (2.0%) car-
ried low- to moderate-risk cancer susceptibility alleles,
APC c.3920T>A (p.Ile1307Lys;35 NM_00038.5), HOXB13
(MIM: 604607; NM_006361.5) c.251G>A/p.Gly84Glu,36
and MITF (MIM: 156845; NM_000248.3) c.952G>A
(p.Glu318Lys)37 (Figure 3A).
To demonstrate the effect of assaying additional genes
associated with AD cancer susceptibility on potential clin-
ical testing outcomes graphically, we determined the pro-
portion of mutation- or VUS-positive families (Figure 3C)
and the increase in identification rates of VUSs and either
LP or P (Figure 3D) in an increasing number of genes. Six
and eight families without identified BRCA1/2 mutations
had LP or P mutations and VUSs, respectively, in high-
risk breast cancer susceptibility genes; therefore, adding
ATM and CHEK2 led to a 2.8-fold increase in the rate of
detection of LP or P mutations in families with a 3.0-fold
increase in VUSs (Figures 3C and 3D). Addition of the
rest of the 16 moderate-penetrance or proposed breast
cancer susceptibility genes led to a cumulative 4.3-fold
increase in LP or P mutations and a cumulative 8.5-fold in-
crease in VUSs. As additional genes associated with AD
cancer susceptibility were added until there were as many
as 99 genes, there was a relatively stable cumulative rate
of LP or P mutations but an increasing cumulative VUS
rate, up to 26-fold the rate in high-risk breast cancer sus-
ceptibility genes alone (Figures 3C and 3D). Similar trends
were observed when the data were expressed as a percent-
age of all individuals or as identified variants (data not
shown).
Larger multiplex panels or medical exome or whole-
exome sequencing can identify mutations in other genes
unrelated to the phenotype under study. We therefore
evaluated the rate of mutations in the non-cancer-associ-
ated genes for which ACMG recommends reporting inci-those associated with AD cancer susceptibility, those associated with
possible attributes leading to our calls and the method of determina
(B) Pie charts showing the percentage of all variants found in LSDBs i
and final calls and LSDBs; likely benign (LB) and benign (B) were cons
considered one call. AD Cancer: genes associated with AD cancer sus
lity.Non-cancer: non-cancer-associated genes,
(C) Pie charts showing the percentage of all LSDB-classified variants w
tial actionability, where B, LB, and VUS (variant of uncertain signifi
P calls were considered potentially clinically actionable.
(D) Heat map showing the individual attributes leading to raw and fi
genes and truncating variants called VUSs in genes where loss of fun
The Amdental findings and the rate of monoallelic mutations in
genes associated with AR cancer susceptibility. In our data-
set, 3.9% and 77% of all 253 families had an incidental LP
or P mutation and VUS, respectively, in a non-cancer-asso-
ciated gene (Table 4). LP or P mutations were identified in
APOB and LDLR, genes associated with familial hyper-
cholesterolemia (MIM: 606945). Other incidental LP or P
mutations were identified in DSP, MYBPC3, and MYL3,
genes associated with cardiomyopathy (MIM: 160790);
PKP2, a gene associated with arrhythmogenic right ven-
tricular dysplasia syndrome; SCN5A, a gene associated
with Brugada syndrome; and CACNA1S, a gene associated
with malignant hyperthermia (MIM: 114208). In addition,
9% of families were monoallelic carriers for a rare LP or P
mutation in a gene associated with AR cancer susceptibility
(genes included FANCD2, GBA, MUTYH, SBDS, and
WAS [MIM: 300392]), and 71% were monoallelic car-
riers of a VUS in a gene associated with AR cancer suscep-
tibility (Table 4). Common pathogenic mutations in
SERPINA1 (NM_001127701.1) c.863A>T (p.Glu288Val)
and c.1096G>A (p.Glu366Lys) were found at 7% and 4%
carrier frequency, respectively, in the dataset, and common
mutations in HFE (NM_000410.3) c.187C>G (p.His63Asp)
and c.845G>A (p.Cys282Tyr) were found at 25% and 8%
carrier frequencies in the dataset, respectively (Table S11).
Dataset carrier frequencies and genotype frequencies for
common HFE mutations were similar to published carrier
and genotype frequencies and/or those found in public
databases (Table S11). When all genes were taken into ac-
count, 75 individuals without identified BRCA1/2 muta-
tions (19%) in 60 families (24%) were found to have at
least one rare LP or P mutation, 95% of individuals in
this study were found to have at least one VUS in one or
more of the 180 assayed genes, and 13% of individuals
had six or more VUSs (Figure 3E).Discussion
Well-established guidelines exist for assessing an inherited
predisposition to breast and ovarian cancer in clinical prac-
tice.1 Genetic testing has traditionally been done after
determination of the most likely cancer susceptibility syn-
drome upon evaluation of clinical characteristics of the
proband (e.g., testing for BRCA1 and BRCA2 mutations in
a family with a history of hereditary breast or ovarianAR cancer susceptibility, and non-cancer-associated genes. The 28
tion are described in Table S2.
n each of nine possible categories of call comparisons between raw
idered one call, and likely pathogenic (LP) and pathogenic (P) were
ceptibility. AR Cancer: genes associated with AR cancer susceptibi-
ith concordant and discordant raw and final calls based on poten-
cance) calls were considered clinically nonactionable and LP and
nal calls of clinically relevant variants, i.e., LP or P variants in all
ction is the mechanism of pathogenesis.
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Figure 2. Rates of Calls According to ACMG Guidelines in 180 Genes in Individuals with Breast Cancer
(A) Overview of the distribution of the five variant classifications in all genes, known or proposed breast cancer susceptibility (BC) genes,
genes associated with AD cancer susceptibility, genes associated with AR inherited cancer susceptibility, and non-cancer-associated
genes. Breast cancer: genes associated with breast cancer susceptibility; AD Cancer: genes associated with AD cancer susceptibility;
AR cancer: genes associated with AR cancer susceptibility; non-cancer: non-cancer-associated genes.
(B) Bar plot showing the absolute number of VUSs and LP and P variants in genes with at least one LP or P mutation in BC genes.
(C) Bar plot showing the absolute number of VUSs and LP and P variants in genes with at least one LP or P mutation in genes associated
with (a/w) AD cancer susceptibility.
(D) Bar plot showing the absolute number of VUSs and LP and P variants in genes with at least one LP or P mutation in genes associated
with (a/w) AR cancer susceptibility.
(E) Bar plot showing the absolute number of VUSs and LP and P variants in genes with at least one LP or P mutation in non-cancer-asso-
ciated genes.
(B–E) F ¼ final calls; R ¼ raw calls.
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Table 3. Number of Available Attributes and Proportion of Variants with Definitive Calls in Gene Classes
Categorya
Average Proportion of Definitive
(B/LB/LP/P) Calls versus VUS Callsb
Average Number of Attributes Available
for Variant Classificationb
Percent p Value Number p Value
Well-defined breast cancer susceptibility
genes (n ¼ 11)
69 2.3
Proposed breast cancer susceptibility genes
(n ¼ 14)
52 NS 1.1 0.003
Genes associated with AD cancer
susceptibility (n ¼ 84)
46 0.002 1.2 0.0002
Incidental (secondary)-disease-associated
genes (n ¼ 32)
42 0.002 0.8 1.95 3 105
Genes associated with AR cancer
susceptibility (n ¼ 39)
29 1.1 3 105 1.6 0.006
aSee Table S1 for genes in each category.
bp compared to value for well-defined breast cancer susceptibility genes.cancer). However, decreases in costs associated with
massively parallel sequencing have led clinical practice to
move toward assaying an increasing number of genes via
multiplex panel testing.12 With the increased utilization
of genetic panel testing, a number of important clinical
challenges have arisen with regard to variant classification,
reporting of VUSs, and incidental (also referred to as sec-
ondary) findings.21,24,38 In this study, we report on ameth-
odology based on ACMG variant-classification guidelines
in a research setting and compare its utility in identifying
potentially clinically reportable variants (VUSs and either
LP or P mutations) in 180 cancer- and non-cancer-associ-
ated genes in a cohort of individuals to the utility of typical
practices for assessing hereditary breast and ovarian cancer
risk. Furthermore, we assess whether the inclusion of addi-
tional cancer susceptibility genes, besides those already
associated with hereditary breast and ovarian cancer, is of
clinical benefit for this population.
Use of our methodology based on ACMG variant-classi-
fication guidelines gave final calls with a high level of
concordance (95%) to well-curated locus-specific databases
when we considered potential clinical actionability. Abso-
lute call concordance was lower than potential actionabil-
ity concordance for all genes in comparisons to LSDBs.
Notably, actionability and absolute concordance was lower
for raw calls than for final calls in all categories, demon-
strating the critical need for expert review of variant classi-
fications.24 The necessity of such review is particularly
important for genes associated with AR cancer susceptibil-
ity, which are often found on expanded carrier screening
panels,39 because the difference between potential action-
ability concordance for raw calls and that for final calls was
greater for genes associated with AR cancer susceptibility
than for either genes associated with AD cancer sus-
ceptibility or non-cancer-associated genes (D þ 14% versus
D þ 3% and D þ 1%, respectively). Our final calls were also
highly concordant (95%) with the Clinvar database when
potential actionability was considered, and absolute
concordance (77%) was again lower for all genes. NearlyThe Amall of the discrepancy was due to B or LB calls that were
classified as VUSs in Clinvar, possibly reflecting the
inherent heterogeneity of Clinvar calls because Clinvar
contains data from multiple submitters. As with LSDBs,
both potential actionability concordance and absolute
concordance with Clinvar calls was lower for raw calls
than for final calls. There are multiple potential reasons
for variant-call overrides; the ones that led to an increased
final-call concordance rate in our study are provided in
Table 2. Overall, our results clearly demonstrate the
requirement of expert judgment in variant-classification
methodologies and provide evidence that fully automated
approaches to the application of the ACMG variant-classi-
fication guidelines, although a goal, might not be ready for
use in clinical practice.
It is important to note that other variant-classification
guidelines have been or probably will be proposed.40
Such guidelines, particularly those that incorporate multi-
level and potentially weighted subscoring systems within
individual attributes as suggested by the ACMG guide-
lines,24 might improve performance. For example, consid-
eration could be given to varying the points awarded for
functional studies based on biochemical versus animal
model systems, the number of years since a pathogenic
gene or variant was published or replicated, the number
of unrelated probands with variants that provide
convincing evidence for disease causality across all curated
literature, and the level of rigor of the LSDB being used as a
reference.
Other studies have evaluated multiplex panels contain-
ing 16–42 genes in populations similar to our study popu-
lation and report mainly on rates of pathogenic mutations
without focusing on all variant classes or classification
methods. These studies have found that between 3.4%
and 11.1% of individuals without identified BRCA1/2
mutations have mutations in other cancer susceptibility
genes, most of which confer a moderate risk of breast or
ovarian cancer.13–18 We found a similar, albeit slightly
higher, mutation rate of 11% in our population, probablyerican Journal of Human Genetics 98, 801–817, May 5, 2016 811
Figure 3. Variation in Mutation Rate in AD Cancer Susceptibility Genes in Families Affected by Breast or Ovarian Cancer
(A) Breakdown of the number of LP or P mutations identified in 389 individuals representing 243 families without identified BRCA1/2
mutations. a/w: associated with.
(B) Proportion of families that did not have identified BRCA1/2mutations and that fit the three main inclusion criteria: history of famil-
ial breast cancer (FBC), history of early-onset breast cancer (EOBC), and history of both breast and ovarian cancer (Br/Ov) along with
high-risk breast cancer susceptibility gene mutations, ATM or CHEK2 mutations, or mutations in the rest of the genes associated with
AD cancer susceptibility. *p < 0.05, **p < 0.01.
(C) Percentage of families with VUSs (gray bars) in indicated genes and percentage of families with LP or P mutations (black bars) in indi-
cated genes, additive from top to bottom. AD non-syndromic: genes associated with AD cancer susceptibility not associated with other
syndromic features; AD syndromic: genes associated with AD cancer susceptibility syndromes.
(D) N-fold increase in the rate of identification of families with LP or P mutations and VUSs as the number of assayed genes associated
with AD cancer susceptibility increases.
(E) Bar plot showing the distribution of individuals with one and up to six or more VUSs identified in the study.as a result of our eligibility criteria, which targeted high-
risk populations, such as those with both primary breast
and ovarian cancers. Reported VUS rates vary widely be-
tween studies, from 19% to 88%. Among others, reasons
for this variation could include differences in variant clas-
sification, selection of assayed genes, or ethnicity variation
in the underlying population. In our study, using our
comprehensive methodology based on ACMG variant-
classification guidelines, we found a 12% VUS rate for
the well-established breast cancer susceptibility genes.
The VUS rate increased significantly, encompassing 78%
of families, when additional genes associated with AD can-
cer susceptibility were analyzed. VUS rates were also high
for the non-cancer-associated genes (77% of families) and812 The American Journal of Human Genetics 98, 801–817, May 5, 2genes associated with AR cancer susceptibility (68% of
families). This observation is most likely due to the
decreased number of attributes supporting these genes’
variant calls as compared to calls of well-established breast
cancer susceptibility genes and to sequencing of genes not
associated with the phenotype of interest. Alternatively,
the VUSs in less well-studied genes might have important
clinical consequences, but both the genes and variants
within might require additional characterization via func-
tional and population-based studies before they can be
moved into the LP or P category.
Whole-exome sequencing studies have shown higher
rates of molecular diagnosis, from 23% to 31%,23,41–46
than the rate of 11% found in this study. It is unlikely016
Table 4. Proportion of Families Found to Have VUSs and LP or P Mutations in Overall Categories
Categorya
Number of Cohort Bb Families
with LP or P Mutations (n ¼ 243)
Number of Cohort Bb Families
with at Least One VUS (n ¼ 243)
Ratio VUS:LP or Pn Percent n Percent
Well-defined breast cancer susceptibility
genes (n ¼ 11)
18 7.4 30 12 2:1
Proposed breast cancer susceptibility genes
(n ¼ 14)
8 3.3 43 18 5:1
Rest of genes associated with AD cancer
susceptibility (n ¼ 84)
2 0.8 189 77 95:1
Number of Cohort A þ Bc families
with LP-P mutations (n ¼ 253)
Number of Cohort A þ B families
with at least one VUS (n ¼ 253)
n Percent n Percent
Incidental-disease-associated genes (n ¼ 32) 10 3.9 195 77 20:1
Genes associated with AR cancer
susceptibility; monoallelic carriers (n ¼ 39)d
23 9.0 173 71 8:1
aSee Table S1 for genes in each category.
bCohort B is the entire cohort of individuals without identified BRCA1/2 mutations.
cCohort A þ B are all families in the study
dExcluding HFE and SERPINA1 common-mutation carriers.that the rate of molecular diagnosis would increase with
analysis of the remaining exome data in our study because
all known genes associated with cancer susceptibility32
were analyzed in this study. This difference is therefore
possibly due to the fact that the aforementioned studies
have predominantly reported clinical whole-exome
sequencing use in pediatric populations for neurological
conditions or birth defects; less than 1%–2% of individuals
in these studies were sequenced on the basis of a concern
about cancer predisposition. Diagnostic pediatric whole-
exome sequencing commonly includes a parent-child
trio, in which the parents are unaffected, and focuses on
identifying novel variants that are associated with a highly
penetrant disease in the child. Identifying mutations
through whole-exome sequencing associated with cancer
predisposition in adults is more complex, in large part
because of the variable penetrance of the disease, which
is most commonly passed from parent to child. The most
informative study design includes distant relatives (at
most third degree), both affected with cancer, in families
demonstrating AD transmission of cancer susceptibility.
However, in clinical practice, such relative pairs are diffi-
cult to identify, and given the commonality of many can-
cer types, phenocopies are often an issue. It is therefore
critical when considering the use of clinical whole-exome
sequencing for evaluation of inherited susceptibility to
cancer to consider that molecular diagnosis rates are likely
to be lower.
A number of studies have evaluated the findings of inci-
dental cancer-associated or non-cancer-associated gene
mutations in individuals undergoing clinical whole-
exome sequencing as above and in population data-
bases.44,47–52 The rate of identification of incidental
mutations in cancer-associated or non-cancer-associated
genes in these populations ranges from 0.7% to 5.8%.The AmWe have found a similar rate of incidental findings;
3.9% of our families with a history of breast or ovarian
cancer have at least one family member with an LP or P
mutation in a non-cancer-associated gene. These data
demonstrate the need for cancer-risk-evaluation clinics
to provide pretest counseling regarding the potential for
incidental findings if medical exome or clinical whole-
exome sequencing is used.
Our study has important limitations. First, we have
evaluated the use of our methodology in a relatively small
cohort of 404 individuals representing 253 families and
have classified variants in 180 genes. Studies using larger
numbers of individuals, variants, and genes are needed
for validation of our results in individuals at high risk
for breast cancer. We classified variants in clinically rele-
vant genes with known or potential roles in inherited dis-
ease; many of these roles are very well characterized. We
conducted our evaluation in individuals with a high likeli-
hood of having an inherited breast or ovarian syndrome,
a disease with relatively well understood genetic suscepti-
bility. This methodology of applying the ACMG variant-
classification guidelines might be not be as useful if
applied in other situations, including those involving
cancer types for which less is known about the genes
and variants associated with inherited susceptibility—for
example, cancer involving genes for which the function
and domains are poorly characterized, genes with un-
known links to disease predisposition, and somatic vari-
ants identified by tumor genomic sequencing. Finally,
the individuals underwent whole-exome sequencing
without an orthogonal validation method. It is possible
that rates of different variant classes in the studied cate-
gories of genes might differ if evaluation is by alternative
sequencing methodologies or incorporates the use of dele-
tion or duplication analysis.erican Journal of Human Genetics 98, 801–817, May 5, 2016 813
The majority of studies demonstrating the clinical
utility of whole-exome or large-multiplex-panel-based
sequencing have been performed in predominantly pedi-
atric populations during assays for neurological disorders.
These studies and those of smaller multiplex panels in
cancer susceptibility cohorts have used a wide variety of
non-standardized variant-classification methodologies.
We have used a methodology based on ACMG variant clas-
sification guidelines in a large number of both cancer sus-
ceptibility and reported non-cancer-associated genes in a
cohort of individuals with susceptibility to breast and
ovarian cancer. The high concordance of variant calls
with LSDBs and Clinvar suggests the clinical utility of
variant classification based on ACMG guidelines coupled
with expert review. In addition, we show that increasing
the number of genes assayed in a population undergoing
testing for cancer susceptibility has minimal clinical
impact and leads to increasing clinical complexity as a
result of increased VUS identification. Our results strongly
support the view that additional research studies are
needed to resolve VUSs and understand the implications
of incidental and/or unexpected results38,53 obtained
from genetic testing for the assessment of cancer suscepti-
bility. Our data do not support the use of medical exome or
whole-exome sequencing for evaluation of cancer suscep-
tibility in individuals at high risk for breast and/or ovarian
cancer at this time; the incremental benefit of potential
mutation identification would be outweighed by the iden-
tification of multiple VUSs.Supplemental Data
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